OMED Disappoints, PBYI Soars, AMAG Seeks Expanded Approval For Makena

Shares of OncoMed Pharmaceuticals Inc. (OMED) slipped more than 17% on Monday, following the failure of its phase II trial of Tarextumab in Small Cell Lung Cancer to meet the endpoints.

from RTT - Biotech http://ift.tt/2nXKHwK
via IFTTT